AKR1A1, ALDR1, ALR, ARM, DD3, HEL-S-6, Aldo-keto reductase family 1, member A1, aldo-keto reductase family 1, member A1 (aldehyde reductase), aldo-keto reductase family 1 member A1
Alcohol dehydrogenase [NADP+] also known as aldehyde reductase or aldo-keto reductase family 1 member A1 is an enzyme that in humans is encoded by the AKR1A1gene.[5][6][7] AKR1A1 belongs to the aldo-keto reductase (AKR) superfamily. It catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphaticaldehydes to their corresponding alcohols and catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol.[8]Mutations in the AKR1A1 gene has been found associated with non-Hodgkin's lymphoma.[9]
Structure
Gene
The AKR1A1 gene lies on the chromosome location of 1p34.1 and consists of 10 exons.
Protein
AKR1A1 consists of 325 amino acids and weighs 36573Da. The tertiary structure consists of a beta/alpha-barrel, with the coenzyme-binding site located at the carboxy-terminus end of the strands of the barrel.[10]Alternative splicing of this gene results in two transcript variants encoding the same protein.[7]
Function
AKR1A1 gene is found highly expressed in kidney and liver, and moderately expressed in cerebrum, small intestine and testis. Small amounts of AKR1A1 are present in lung, prostate and spleen. However, it is not observed in heart or skeletal muscle.[11] AKR1A1 belongs to the AKR superfamily, which are predominantly monomeric, soluble, NADPH-dependent oxidoreductases involved in the reduction of aldehydes and ketones into primary and secondary alcohols.[12] AKR1A1 is shown to demonstrate characteristically high specific activity towards many aromatic and aliphatic aldehydes,[11] and preferentially catalyses the NADPH-dependent reduction of aliphatic aldehydes, aromatic aldehydes and biogenic amines.[13][14][15] It is also reported to be involved in the metabolism of 4-hydroxynonenal and play a role in the resistance to oxidative stress.[16]
Clinical significance
A SNP in intron 5 of AKR1A1 has been found to be significantly associated with increased risk of non-Hodgkin's lymphoma.[9] AKR1A1 could activate procarcinogens, such as polycyclic aromatic hydrocarbon.[8] AKRs have been linked to metabolism of the anthracyclinesdoxorubicin (DOX) and daunorubicin (DAUN), allelic variants showed significantly reduced metabolic activities, and hence these allelic variants can possibly act as genetic biomarkers for the clinical development of DAUN-induced cardiotoxicity.[17]
^Fujii J, Hamaoka R, Matsumoto A, Fujii T, Yamaguchi Y, Egashira M, Miyoshi O, Niikawa N, Taniguchi N (Jul 1999). "The structural organization of the human aldehyde reductase gene, AKR1A1, and mapping to chromosome 1p33→p32". Cytogenetics and Cell Genetics. 84 (3–4): 230–2. doi:10.1159/000015265. PMID10393438. S2CID34254843.
^Feather MS, Flynn TG, Munro KA, Kubiseski TJ, Walton DJ (May 1995). "Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase". Biochimica et Biophysica Acta (BBA) - General Subjects. 1244 (1): 10–6. doi:10.1016/0304-4165(94)00156-r. PMID7766643.
^ abLi D, Zhang Q, Zhou L, Liu R (March 2013). "[Effect of AKR1A1 knock-down on H2;O2; and 4-hydroxynonenal-induced cytotoxicity in human 1321N1 astrocytoma cells]". Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology. 29 (3): 273–6. PMID23643085.
^ abBains OS, Takahashi RH, Pfeifer TA, Grigliatti TA, Reid RE, Riggs KW (May 2008). "Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin". Drug Metabolism and Disposition. 36 (5): 904–10. doi:10.1124/dmd.107.018895. PMID18276838. S2CID14214962.
Further reading
Dawson SJ, White LA (May 1992). "Treatment of Haemophilus aphrophilus endocarditis with ciprofloxacin". The Journal of Infection. 24 (3): 317–20. doi:10.1016/S0163-4453(05)80037-4. PMID1602151.
Tanimoto T, Ohta M, Tanaka A, Ikemoto I, Machida T (1991). "Purification and characterization of human testis aldose and aldehyde reductase". The International Journal of Biochemistry. 23 (4): 421–8. doi:10.1016/0020-711X(91)90169-N. PMID1901806.
Wermuth B, Omar A, Forster A, di Francesco C, Wolf M, von Wartburg JP, Bullock B, Gabbay KH (1987). "Primary structure of aldehyde reductase from human liver". Progress in Clinical and Biological Research. 232: 297–307. PMID3615425.
Barski OA, Gabbay KH, Grimshaw CE, Bohren KM (September 1995). "Mechanism of human aldehyde reductase: characterization of the active site pocket". Biochemistry. 34 (35): 11264–75. doi:10.1021/bi00035a036. PMID7669785.
Barski OA, Gabbay KH, Bohren KM (September 1999). "Characterization of the human aldehyde reductase gene and promoter". Genomics. 60 (2): 188–98. doi:10.1006/geno.1999.5915. PMID10486210.
Laclau M, Lu F, MacDonald MJ (September 2001). "Enzymes in pancreatic islets that use NADP(H) as a cofactor including evidence for a plasma membrane aldehyde reductase". Molecular and Cellular Biochemistry. 225 (1–): 151–60. doi:10.1023/A:1012238709063. PMID11716357. S2CID38935230.
Bohren KM, Brownlee JM, Milne AC, Gabbay KH, Harrison DH (May 2005). "The structure of Apo R268A human aldose reductase: hinges and latches that control the kinetic mechanism". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1748 (2): 201–12. doi:10.1016/j.bbapap.2005.01.006. PMID15769597.